Rezolute Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update
Provided By GlobeNewswire
Last update: May 13, 2025
sunRIZE enrollment on track including U.S. sites and expected to be completed in May 2025; topline data anticipated in December 2025
U.S. Food and Drug Administration (FDA) grants Breakthrough Therapy Designation to ersodetug for hypoglycemia due to tumor hyperinsulinism
Read more at globenewswire.com
